One Day Advisor

Reviewed by: Frank Yap, MBA  |  Written by: One Day Advisor Editorial Team  |  Originally published: July 1, 2026  |  Last updated: October 2026 Disclosure: This article is educational and is not financial or investment advice. Cryptocurrency is highly volatile and you can lose your entire investment. It contains no affiliate or sponsored links. Other One Day Advisor pages may include Amazon Associates links, which are disclosed where they appear. Quick Answer The 1,064/364-day model says Bitcoin rises about 1,064 days from a cycle low to a peak, then falls about 364 days to the next low. Applied to the October 6, 2025 peak (about $126,200), it pointed to a bottom near October 5, 2026. So far the low was about $57,800 on July 1, 2026, and Bitcoin trades near $81,000. What changed in this update (October 24, 2026) Added the model’s origin (analyst Ali Martinez) and its original October 2026 / $37,500 call. Replaced the historical table, which...

Last updated: October 2026 The obesity drug market is becoming a competition not just to discover the next blockbuster medicine, but to acquire, license and combine the next generation of weight-loss technologies. The first wave of transactions gave large pharmaceutical companies access to GLP-1 and GIP receptor agonists. The next wave is broader: oral small-molecule drugs, amylin analogues, triple agonists, less-frequent injections and mechanisms that might reduce fat while preserving lean mass. The strategic question is changing. Instead of simply asking which biotech has the largest reported weight-loss result, buyers must ask which company owns differentiated assets, which assets are close enough to commercialization to justify their price, and which pipeline can complement an existing commercial franchise. This map separates completed acquisitions from licensing deals and collaborations. It then compares three publicly traded obesity-focused biotechs—Viking Therapeutics, S...

Which industries could lose as Ozempic, Wegovy, Mounjaro, and Zepbound change appetite, food spending, and obesity care? Compare six sectors, their GLP-1 exposure scores, illustrative stock baskets, and the evidence behind the investment thesis. OneDayAdvisor research framework · Updated October 24, 2026 GLP-1 medicines are no longer just a pharmaceutical-industry story. By changing appetite, body weight, and metabolic health, these medicines could influence industries ranging from packaged snacks and alcoholic beverages to bariatric surgery, sleep-apnea treatment, orthopedic procedures, and kidney care. For investors, the important question is not simply which businesses are associated with obesity. It is which companies could experience measurable changes in product volumes, procedure demand, or long-term healthcare utilization as GLP-1 medicines become more widely used. The clearest current consumer-sector signal is in some packaged-food categories. Bariatric s...